{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:21:14Z","timestamp":1772166074706,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>COVID-19 vaccines have been crucial in the pandemic response and understanding changes in vaccines effectiveness is essential to guide vaccine policies. Although the Delta variant is no longer dominant, understanding vaccine effectiveness properties will provide essential knowledge to comprehend the development of the pandemic and estimate potential changes over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this population-based cohort study, we estimated the vaccine effectiveness of Comirnaty (Pfizer\/BioNTech; BNT162b2), Spikevax (Moderna; mRNA-1273), Vaxzevria (AstraZeneca; ChAdOx nCoV-19; AZD1222), or a combination against SARS-CoV-2 infections, hospitalisations, intensive care admissions, and death using Cox proportional hazard models, across different vaccine product regimens and age groups, between 15 July and 31 November 2021 (Delta variant period). Vaccine status is included as a time-varying covariate and all models were adjusted for age, sex, comorbidities, county of residence, country of birth, and living conditions. Data from the entire adult Norwegian population were collated from the National Preparedness Register for COVID-19 (Beredt C19).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The overall adjusted vaccine effectiveness against infection decreased from 81.3% (confidence interval (CI): 80.7 to 81.9) in the first 2 to 9\u00a0weeks after receiving a second dose to 8.6% (CI: 4.0 to 13.1) after more than 33 weeks, compared to 98.6% (CI: 97.5 to 99.2) and 66.6% (CI: 57.9 to 73.6) against hospitalisation respectively. After the third dose (booster), the effectiveness was 75.9% (CI: 73.4 to 78.1) against infection and 95.0% (CI: 92.6 to 96.6) against hospitalisation. Spikevax or a combination of mRNA products provided the highest protection, but the vaccine effectiveness decreased with time since vaccination for all vaccine regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Even though the vaccine effectiveness against infection waned over time, all vaccine regimens remained effective against hospitalisation after the second vaccine dose. For all vaccine regimens, a booster facilitated recovery of effectiveness. The results from this support the use of heterologous schedules, increasing flexibility in vaccination policy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-022-02480-4","type":"journal-article","created":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T20:02:37Z","timestamp":1662062557000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July\u2013November 2021"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3714-4844","authenticated-orcid":false,"given":"Jostein","family":"Starrfelt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders Skyrud","family":"Danielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eirik Alnes","family":"Buanes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lene Kristine","family":"Juvet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trude Marie","family":"Lyngstad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnar \u00d8yvind Isaksson","family":"R\u00f8","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lamprini","family":"Veneti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara Viksmoen","family":"Watle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hinta","family":"Meijerink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,2]]},"reference":[{"issue":"5","key":"2480_CR1","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403\u201316.","journal-title":"N Engl J Med"},{"issue":"27","key":"2480_CR2","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603\u201315.","journal-title":"N Engl J Med"},{"issue":"19","key":"2480_CR3","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","volume":"385","author":"SJ Thomas","year":"2021","unstructured":"Thomas SJ, Moreira ED Jr, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine through 6 months. N Engl J Med. 2021;385(19):1761\u201373.","journal-title":"N Engl J Med"},{"issue":"37","key":"2480_CR4","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.15585\/mmwr.mm7037e1","volume":"70","author":"HM Scobie","year":"2021","unstructured":"Scobie HM, Johnson AG, Suthar AB, et al. Monitoring incidence of COVID-19 cases, hospitalizations, and deaths, by vaccination status - 13 U.S. Jurisdictions, April 4-July 17, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(37):1284\u201390.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"9","key":"2480_CR5","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3390\/vaccines9090989","volume":"9","author":"YJ Fan","year":"2021","unstructured":"Fan YJ, Chan KH, Hung IF. Safety and efficacy of COVID-19 vaccines: a systematic review and meta-analysis of different vaccines at phase 3. Vaccines (Basel). 2021;9(9):989.","journal-title":"Vaccines (Basel)"},{"issue":"6","key":"2480_CR6","doi-asserted-by":"publisher","first-page":"ofac138","DOI":"10.1093\/ofid\/ofac138","volume":"9","author":"MM Higdon","year":"2022","unstructured":"Higdon MM, Wahl B, Jones CB, et al. A systematic review of coronavirus disease 2019 vaccine efficacy and effectiveness against severe acute respiratory syndrome coronavirus 2 infection and disease. Open Forum Infect Dis. 2022;9(6):ofac138.","journal-title":"Open Forum Infect Dis"},{"key":"2480_CR7","doi-asserted-by":"publisher","unstructured":"Gram MA, Nielsen J, Schelde AB, et al. Vaccine effectiveness when combining the ChAdOx1 vaccine as the first dose with an mRNA COVID-19 vaccine as the second dose. medRxiv. 2021. https:\/\/doi.org\/10.1371\/journal.pmed.1003874.","DOI":"10.1371\/journal.pmed.1003874"},{"issue":"4","key":"2480_CR8","doi-asserted-by":"publisher","first-page":"e3001211","DOI":"10.1371\/journal.pbio.3001211","volume":"19","author":"SM Moghadas","year":"2021","unstructured":"Moghadas SM, Vilches TN, Zhang K, et al. Evaluation of COVID-19 vaccination strategies with a delayed second dose. PLoS Biol. 2021;19(4):e3001211.","journal-title":"PLoS Biol"},{"key":"2480_CR9","doi-asserted-by":"crossref","unstructured":"Puranik A, Lenehan PJ, Silvert E, et al. Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. medRxiv. 2021.","DOI":"10.1101\/2021.08.06.21261707"},{"issue":"35","key":"2480_CR10","doi-asserted-by":"publisher","first-page":"2100793","DOI":"10.2807\/1560-7917.ES.2021.26.35.2100793","volume":"26","author":"E Seppala","year":"2021","unstructured":"Seppala E, Veneti L, Starrfelt J, et al. Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021. Euro Surveill. 2021;26(35):2100793.","journal-title":"Euro Surveill"},{"issue":"10293","key":"2480_CR11","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(21)01358-1","volume":"397","author":"A Sheikh","year":"2021","unstructured":"Sheikh A, McMenamin J, Taylor B, Robertson C. Public Health S, the EIIC. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021;397(10293):2461\u20132.","journal-title":"Lancet"},{"issue":"10","key":"2480_CR12","doi-asserted-by":"publisher","first-page":"e0258513","DOI":"10.1371\/journal.pone.0258513","volume":"16","author":"L Veneti","year":"2021","unstructured":"Veneti L, Sepp\u00e4l\u00e4 E, Larsdatter Storm M, et al. Increased risk of hospitalisation and intensive care admission associated with reported cases of SARS-CoV-2 variants B.1.1.7 and B.1.351 in Norway, December 2020 -May 2021. PLoS One. 2021;16(10):e0258513.","journal-title":"PLoS One"},{"key":"2480_CR13","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ijid.2021.12.321","volume":"115","author":"L Veneti","year":"2022","unstructured":"Veneti L, Valcarcel Salamanca B, Sepp\u00e4l\u00e4 E, et al. No difference in risk of hospitalization between reported cases of the SARS-CoV-2 Delta variant and Alpha variant in Norway. Int J Infect Dis. 2022;115:178\u201384.","journal-title":"Int J Infect Dis"},{"issue":"7867","key":"2480_CR14","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/d41586-021-01805-2","volume":"595","author":"D Lewis","year":"2021","unstructured":"Lewis D. Mix-and-match COVID vaccines: the case is growing, but questions remain. Nature. 2021;595(7867):344\u20135.","journal-title":"Nature"},{"issue":"3","key":"2480_CR15","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.coi.2009.05.016","volume":"21","author":"S Lu","year":"2009","unstructured":"Lu S. Heterologous prime-boost vaccination. Curr Opin Immunol. 2009;21(3):346\u201351.","journal-title":"Curr Opin Immunol"},{"key":"2480_CR16","doi-asserted-by":"publisher","first-page":"n1114","DOI":"10.1136\/bmj.n1114","volume":"373","author":"A Potteg\u00e5rd","year":"2021","unstructured":"Potteg\u00e5rd A, Lund LC, Karlstad \u00d8, et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. BMJ. 2021;373:n1114.","journal-title":"BMJ"},{"issue":"9","key":"2480_CR17","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/S1473-3099(21)00420-5","volume":"21","author":"M Tenbusch","year":"2021","unstructured":"Tenbusch M, Schumacher S, Vogel E, et al. Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2. Lancet Infect Dis. 2021;21(9):1212\u20133.","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"2480_CR18","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1056\/NEJMc2110716","volume":"385","author":"J Normark","year":"2021","unstructured":"Normark J, Vikstrom L, Gwon YD, et al. Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination. N Engl J Med. 2021;385(11):1049\u201351.","journal-title":"N Engl J Med"},{"key":"2480_CR19","doi-asserted-by":"publisher","first-page":"100249","DOI":"10.1016\/j.lanepe.2021.100249","volume":"11","author":"P Nordstr\u00f6m","year":"2021","unstructured":"Nordstr\u00f6m P, Ballin M, Nordstr\u00f6m A. Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study. Lancet Reg Health Eur. 2021;11:100249.","journal-title":"Lancet Reg Health Eur"},{"key":"2480_CR20","doi-asserted-by":"publisher","unstructured":"Goldberg Y, Mandel M, Bar-On YM, et al. Waning immunity of the BNT162b2 vaccine: a nationwide study from Israel. medRxiv. 2021:2021.08.24.21262423. https:\/\/doi.org\/10.1056\/NEJMoa2114228.","DOI":"10.1056\/NEJMoa2114228"},{"issue":"24","key":"2480_CR21","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1056\/NEJMoa2114583","volume":"385","author":"EG Levin","year":"2021","unstructured":"Levin EG, Lustig Y, Cohen C, et al. Waning immune humoral response to BNT162b2 COVID-19 vaccine over 6 months. N Engl J Med. 2021;385(24):e84.","journal-title":"N Engl J Med"},{"issue":"10328","key":"2480_CR22","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","volume":"399","author":"DR Feikin","year":"2022","unstructured":"Feikin DR, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022;399(10328):924\u201344.","journal-title":"Lancet"},{"issue":"4","key":"2480_CR23","doi-asserted-by":"publisher","first-page":"2200077","DOI":"10.2807\/1560-7917.ES.2022.27.4.2200077","volume":"27","author":"L Veneti","year":"2022","unstructured":"Veneti L, B\u00f8\u00e5s H, Br\u00e5then Kristoffersen A, et al. Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022. Eurosurveillance. 2022;27(4):2200077.","journal-title":"Eurosurveillance"},{"issue":"3","key":"2480_CR24","doi-asserted-by":"publisher","first-page":"e0265812","DOI":"10.1371\/journal.pone.0265812","volume":"17","author":"F Methi","year":"2022","unstructured":"Methi F, Hern\u00e6s KH, Skyrud KD, Magnusson K. Pandemic trends in health care use: From the hospital bed to self-care with COVID-19. PLOS ONE. 2022;17(3):e0265812.","journal-title":"PLOS ONE"},{"issue":"6","key":"2480_CR25","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.cmi.2022.01.033","volume":"28","author":"R Whittaker","year":"2022","unstructured":"Whittaker R, Br\u00e5then Kristofferson A, Valcarcel Salamanca B, et al. Length of hospital stay and risk of intensive care admission and in-hospital death among COVID-19 patients in Norway: a register-based cohort study comparing patients fully vaccinated with an mRNA vaccine to unvaccinated patients. Clin Microbiol Infect. 2022;28(6):871\u20138.","journal-title":"Clin Microbiol Infect"},{"key":"2480_CR26","unstructured":"R Core Team. A language and environment for statistical computing. 2021.\u00a0https:\/\/www.R-project.org\/."},{"key":"2480_CR27","unstructured":"Therneau TM. A package for survival analysis in R, 2021. https:\/\/CRAN.R-project.org\/package=survival."},{"issue":"1","key":"2480_CR28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/EDE.0000000000001116","volume":"31","author":"H Chua","year":"2020","unstructured":"Chua H, Feng S, Lewnard JA, et al. The use of test-negative controls to monitor vaccine effectiveness: a systematic review of methodology. Epidemiology. 2020;31(1):43\u201364.","journal-title":"Epidemiology"},{"key":"2480_CR29","doi-asserted-by":"publisher","unstructured":"Poukka E, Baum U, Palmu AA, et al. Cohort study of COVID-19 vaccine effectiveness among healthcare workers in Finland, December 2020 - October 2021. medRxiv. 2021:2021.11.03.21265791. https:\/\/doi.org\/10.1016\/j.vaccine.2021.12.032.","DOI":"10.1016\/j.vaccine.2021.12.032"},{"issue":"10309","key":"2480_CR30","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S0140-6736(21)02183-8","volume":"398","author":"SY Tartof","year":"2021","unstructured":"Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398(10309):1407\u201316.","journal-title":"Lancet"},{"issue":"39","key":"2480_CR31","doi-asserted-by":"publisher","first-page":"2100894","DOI":"10.2807\/1560-7917.ES.2021.26.39.2100894","volume":"26","author":"I Martinez-Baz","year":"2021","unstructured":"Martinez-Baz I, Trobajo-Sanmartin C, Miqueleiz A, et al. Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021. Euro Surveill. 2021;26(39):2100894.","journal-title":"Euro Surveill"},{"key":"2480_CR32","doi-asserted-by":"publisher","unstructured":"Lin D-Y, Gu Y, Wheeler B, et al. Effectiveness of COVID-19 vaccines in the United States over 9 months: surveillance data from the state of North Carolina. medRxiv. 2021:2021.10.25.21265304. https:\/\/doi.org\/10.1056\/NEJMoa2117128.","DOI":"10.1056\/NEJMoa2117128"},{"key":"2480_CR33","doi-asserted-by":"publisher","unstructured":"Nordstr\u00f6m P, Ballin M, Nordstr\u00f6m A. Effectiveness of COVID-19 vaccination against risk of symptomatic infection, hospitalization, and death up to 9 months: a Swedish total-population cohort study. Hosp Death Up. 2021;9. https:\/\/doi.org\/10.1016\/S0140-6736(22)00089-7.","DOI":"10.1016\/S0140-6736(22)00089-7"},{"issue":"4","key":"2480_CR34","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1056\/NEJMoa2115481","volume":"386","author":"N Andrews","year":"2022","unstructured":"Andrews N, Tessier E, Stowe J, et al. Duration of protection against mild and severe disease by COVID-19 vaccines. N Engl J Med. 2022;386(4):340\u201350.","journal-title":"N Engl J Med"},{"key":"2480_CR35","doi-asserted-by":"publisher","first-page":"e069052","DOI":"10.1136\/bmj-2021-069052","volume":"376","author":"M Fabiani","year":"2022","unstructured":"Fabiani M, Puopolo M, Morciano C, et al. Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe COVID-19 during predominant circulation of the Delta variant in Italy: retrospective cohort study. BMJ. 2022;376:e069052.","journal-title":"BMJ"},{"issue":"10327","key":"2480_CR36","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S0140-6736(22)00089-7","volume":"399","author":"P Nordstrom","year":"2022","unstructured":"Nordstrom P, Ballin M, Nordstrom A. Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden. Lancet. 2022;399(10327):814\u201323.","journal-title":"Lancet"},{"key":"2480_CR37","doi-asserted-by":"publisher","first-page":"100208","DOI":"10.1016\/j.lanepe.2021.100208","volume":"10","author":"P Naaber","year":"2021","unstructured":"Naaber P, Tserel L, Kangro K, et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg Health Eur. 2021;10:100208.","journal-title":"Lancet Reg Health Eur"},{"issue":"7821","key":"2480_CR38","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41586-020-2550-z","volume":"584","author":"N Le Bert","year":"2020","unstructured":"Le Bert N, Tan AT, Kunasegaran K, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020;584(7821):457\u201362.","journal-title":"Nature"},{"key":"2480_CR39","doi-asserted-by":"publisher","unstructured":"Skowronski DM, Setayeshgar S, Febriani Y, et al. Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada. medRxiv. 2021:2021.10.26.21265397. https:\/\/doi.org\/10.1093\/cid\/ciac290.","DOI":"10.1093\/cid\/ciac290"},{"key":"2480_CR40","doi-asserted-by":"publisher","unstructured":"Andrews N, Tessier E, Stowe J, et al. Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK. medRxiv. 2021:2021.09.15.21263583. https:\/\/doi.org\/10.1056\/NEJMoa2115481.","DOI":"10.1056\/NEJMoa2115481"},{"key":"2480_CR41","unstructured":"European Centre for Disease Prevention and Control. Interim public health considerations for the provision of additional COVID-19 vaccine doses, 2021. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/covid-19-public-health-considerations-additional-vaccine-doses#no-link, https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/Interim-public-health-considerations-for-the-provision-of-additional-COVID-19-vaccine-doses.pdf."},{"key":"2480_CR42","volume-title":"Seroprevalence of SARS-CoV-2 in the Norwegian population measured in residual sera collected in January 2021","author":"G Tunheim","year":"2021","unstructured":"Tunheim G, Kran A-MB, R\u00f8 G, et al. Seroprevalence of SARS-CoV-2 in the Norwegian population measured in residual sera collected in January 2021. Oslo: The Norwegian Institute of Public Health; 2021."},{"issue":"1","key":"2480_CR43","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/bimj.4710370103","volume":"37","author":"M Haber","year":"1995","unstructured":"Haber M, Halloran ME, Longini IM Jr, Watelet L. Estimation of vaccine efficacy in non-randomly mixing populations. Biometr J. 1995;37(1):25\u201338.","journal-title":"Biometr J"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02480-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-022-02480-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02480-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T20:03:19Z","timestamp":1662062599000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-022-02480-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,2]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2480"],"URL":"https:\/\/doi.org\/10.1186\/s12916-022-02480-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.03.29.22273086","asserted-by":"object"},{"id-type":"doi","id":"10.1101\/2021.11.12.21266222","asserted-by":"object"}]},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,2]]},"assertion":[{"value":"13 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was granted by Regional Committees for Medical and Health Research Ethics (REC) Southeast (reference number 122745). The Norwegian Institute of Public Health has performed a Data Protection Impact Assessment (DPIA) for Beredt C19.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"278"}}